A 2015 Myeloma Therapy Preview with Dr. Robert Orlowski

A 2015 Myeloma Therapy Preview with Dr. Robert Orlowski
Event Description
Dr. Robert Z. Orlowski, MD, PhD MD Anderson Cancer Center Interview Date: January 9, 2015
Dr. Orlowski begins the new year by highlighting some of the most important myeloma therapies that will take us into 2015. He reminds us of the new International Myeloma Working Group guidelines that allow for earlier treatment in smoldering myeloma without waiting for CRAB features. He notes that MRIs will be a critical tool for smoldering myeloma patients to make this determination. He notes the important results of the ASPIRE study of carfilzomib/lenalidomide/dex, telling us that it gave progression-free survival for two years, even in the relapsed/refractory setting. To put that in perspective, this used to be only accomplished with transplant in the newly diagnosed setting. He describes how treatment is becoming more tailored and uses the example of how immunophenotyping can tell if the plasma cells in the bone marrow are normal or not post-treatment. He predicts that two new immunotherpaies (elotuzumab and daratumumab) may be approved in 2015. The appeal of these immunotherapies are that they target myeloma cells that are in virtually all patients, for maximum effect. He also shares the excitement around CAR T and CAR NK cell therapies in myeloma. He shares the development of new oral proteasome inhibitors to make treatment more convenient for patients and highlights two new inhibitors that are showing impact on their own that will be therapies to watch in the new year. The Myeloma Crowd Radio Show with Dr. Robert Z. Orlowski
Schedule & Agenda
Speakers & Moderators

Robert Z. Orlowski, M.D., Ph.D., is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include pathobiology of, novel therapeutic targets and mechanisms of drug resistance in myeloma which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials, and appointed Myeloma Committee Chair for SWOG.

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org






Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.